The New Delhi arm of the international R3 Stem Cell network, offering umbilical cord derived mesenchymal stem cell and exosome treatments for a broad list of conditions.
R3 Stem Cell India is the Indian arm of R3 Stem Cell, an international regenerative medicine network. According to the site, the New Delhi centre sits at Y-49, Internal Road, Hauz Khas, in South Delhi, and can be reached on an Indian telephone number as well as through the network's United States line.
The site states that treatment is built around umbilical cord derived mesenchymal stem cells (adult stem cells taken from donated umbilical cord tissue) and stem cell exosomes (small packages released by cells). It says these are given in several ways depending on the problem being treated, including an intravenous drip, injection into a specific joint or site, a nebuliser or nasal route for lung conditions, and an intrathecal injection into the spinal fluid for neurological conditions. Platelet rich plasma, prepared from the patient's own blood, is also listed.
The clinic advertises treatment for more than forty conditions, spanning diabetes, chronic obstructive pulmonary disease, kidney failure, heart disease, liver disease, arthritis and back pain, and neurological conditions including Parkinson's disease, Alzheimer's disease, multiple sclerosis, stroke and autism. As with all providers in this directory, these are the conditions the site says it treats; they are not evidence that the treatments work, and most of these uses are not established therapies.
The site does not name any individual doctor, surgeon or scientist at the New Delhi centre. It refers only to an unnamed 'team of India stem cell specialists' and 'expert stem cell doctors'. It also does not name a partner hospital or state when the Indian centre opened. Patients should ask directly who would be responsible for their care and where the procedure would take place.
The site lists more than forty conditions for which it offers treatment, including the following.
The site states that its India programme is based on umbilical cord derived mesenchymal stem cells and stem cell exosomes rather than on cells taken from the patient.
The site names no individual clinician at the New Delhi centre; it refers only to an unnamed team of specialists.
The site describes a centre at a ground floor address in Hauz Khas, South Delhi, and gives an Indian telephone number alongside the network's United States number. It does not describe the premises, name a partner hospital, or say whether the laboratory that prepares the cells is on site. It gives no accreditation for the Indian location.
The site states that treatment packages start from 175,000 Indian rupees. It does not break this down or say what a full course would cost.
Profile compiled from information published on the clinic's own website and from the StemCell Registry directory record. Details may change; confirm directly with the clinic before making decisions.